BMO Capital raised its price target on AstraZeneca (NYSE: AZN) to $45.00 (from $41.00) while maintaining an Outperform rating.Analyst Alex ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE